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Abstract
Treatment for glioblastoma consists of radiotherapy and temozolomide-based chemotherapy. However, virtually
all patients recur, leading to a fatal outcome. Receptor tyrosine kinase (RTK)–targeted therapy has been the focus
of attention in novel treatment options for these patients. Here, we compared the efficacy of imatinib, sunitinib,
and cediranib in glioblastoma models. In the present work, the biologic effect of the drugs was screened by viability,
cell cycle, apoptosis, migration, and invasion in vitro assays or in vivo by chick chorioallantoic membrane assay.
Intracellular signaling was assessed by Western blot and the RTK targets were identified using phospho-RTK arrays.
The amplified status of KIT, PDGFRA, and VEGFR2 genes was assessed by quantitative polymerase chain reaction. In
a panel of 10 glioblastoma cell lines, we showed that cediranib was the most potent. In addition, cediranib and
sunitinib synergistically sensitize the cells to temozolomide. Cediranib efficacy was shown to associate with higher
cytostatic and unique cytotoxic effects in vitro and both antitumoral and antiangiogenic activity in vivo, which could
associate with its great capacity to inhibit mitogen-activated protein kinase (MAPK) and AKT pathways. Themolecular
status of KIT, PDGFRA, and VEGFR2 did not predict glioblastoma cell responsiveness to any of the RTK inhibitors.
Importantly, phospho-RTK arrays revealed novel targets for cediranib and sunitinib therapy. In conclusion, the novel
targets found may be of value as future biomarkers for therapy response in glioblastoma and lead to the rational
selection of patients for effective molecular targeted treatment.
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Introduction
Brain tumors represent the leading cause of cancer-related death in
children and the fourth in middle-aged men [1]. Gliomas are the
most frequent, accounting for approximately 70% of all primary
brain tumors. According to the World Health Organization, gliomas
can be divided in four grades of malignancy and three histologic sub-
types, being astrocytoma grade IV (glioblastoma) the most common
subtype [2,3]. Glioblastomas are among the most lethal tumors, with
median survival of approximately 16 months, despite aggressive sur-
gery, radiotherapy, and chemotherapy [4]. So far, temozolomide, a
cytotoxic drug, remains the only anticancer agent that has improved
outcome, but almost all glioblastoma patients eventually develop tumor
recurrence, resulting in death [5]. Therefore, it is imperative to improve
the treatment options for glioblastoma.
Currently, there are great expectations on the translation of glioma
biology [2,3] to the development of agents that target key glioma
players, such as receptor tyrosine kinases (RTKs) [6]. As previously
demonstrated by us and others, epidermal growth factor receptor
(EGFR) alterations are the most common genetic abnormalities in
malignant gliomas, alterations of 4q12 region, namely the PDGFRA,
KIT, and vascular endothelial growth factor receptor 2 (VEGFR2)
(KDR) amplicon, which are also frequently upregulated [7–9]. Inter-
estingly, several recent studies showed that gliomas, and particularly
glioblastomas, exhibit intratumoral heterogeneity of RTK (EGFR,
PDGFRA, and MET) alterations, with individual tumors displaying
co-amplification of RTKs, yet, different cells showing amplification
of a different RTK [10–12]. Thus, inhibition of multiple RTKs con-
stitutes a rational approach for treatment of these cancers. Addition-
ally, glioblastomas are among the most human vascularized tumors,
and endothelial proliferation is pathognomonic of these tumors [13].
Hence, combination of antineoplastic with antiangiogenic therapies
constitutes an attractive approach [14].
Small-molecule compounds, such as imatinib, that inhibit the kinase
domain of specific kinase targets have recently changed clinical practice
for several advanced cancers. It has been used in the context of chronic
myeloid leukemia by inhibiting the BCR-ABL fusion protein [15] and
for gastrointestinal stromal tumors by inhibition of the activating KIT
mutations [16]. Other drugs have been also successfully used, such as
sunitinib, which inhibits VEGFR and PDGFR in metastatic renal cell
carcinoma [17], and sorafenib, which targets Raf, PDGFR, VEGFR,
and KIT in advanced hepatocellular carcinoma [18].
The ability of imatinib to inhibit PDGFR signaling has suggested
a potential therapeutic benefit in glioblastoma. However, imatinib
clinical trials showed absence or minimal therapeutic activity [19,20].
Recently, single-target bevacizumab, a humanized monoclonal anti-
body against VEGF, was approved by the Food and Drug Adminis-
tration (FDA) for treatment of recurrent glioblastoma [21]. Although
bevacizumab prolonged progression-free survival, resistance to anti-
angiogenic (or anti-VEGF) therapy is expected [22]. Furthermore, pre-
clinical models suggest that anti-VEGF therapy can induce a previously
noninvasive glioma tumor to invade normal brain [23]. Therefore,
single-agent activity is questionable in the treatment of glioblastomas,
and it is currently believed that multi-kinase inhibitors, which target
several RTKs simultaneously—pan-RTK inhibitors (RTKis)—may
yield greater clinical efficacy [12,24].
Sunitinib malate (SU11248, Sutent by Pfizer, New York, NY) is a
small orally bioavailable molecule that has been identified as an inhibitor
of the PDGFR-α/β, VEGFR1–3, KIT, RET, FLT3, and CSF1R RTKs
[25]. Sunitinib has demonstrated activity in glioma preclinical mouse
models [26–31] and in phase II clinical trials [32]. Cediranib
(AZD2171, Recentin by AstraZeneca, London, United Kingdom) is a
potent inhibitor of VEGFRs, which also targets KIT and PDGFRA
[33,34]. Cediranib showed promising results in gliomas, leading to
6-month progression-free survival in phase II clinical trials [35]. The
efficacy of cediranib has been related to its antiangiogenic capability
and ability to normalize tumor vasculature and alleviate edema in
glioma patients [36–38]. Despite the promise that the abovementioned
drugs hold, the identification of biomarkers for response prediction to
those therapies is a major issue that remains to be addressed.
In the present work, we first aimed to compare the therapeutic
and biologic impact of three main RTKis, cediranib, sunitinib, and
imatinib, in in vitro and in vivo glioblastoma models and to identify
the major RTK targets in glioblastomas cells, thereby fostering the
identification of potential predictive biomarkers for therapy response
to these RTKis in glioblastoma.
Materials and Methods
Cell Lines and Cell Culture
Eight immortalized glioblastoma cell lines were used: SW1088,
SW1783, U-87 MG, and A172 were obtained from American Type
Culture Collection (ATCC, Manassas, VA), SNB-19 and GAMG
were obtained from DSMZ (German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany), and U251 and U373
were kindly provided by Professor Joseph Costello. All the cell lines
were maintained in Dulbecco’s modified Eagle’s medium (DMEM
1×, high glucose; Gibco, Invitrogen, Grand Island, NY) supplemented
with 10% FBS (Gibco, Invitrogen) and 1% penicillin/streptomycin
solution (DMEM-10), at 37°C and 5%CO2 [39]. Additionally, primary
tumor cell cultures were derived from glioblastoma surgical biopsies ob-
tained at the Neurosurgery Department of Barretos Cancer Hospital
(São Paulo, Brazil). The study protocol was approved by the local Ethics
Committee, and patients signed an informed consent form. Each tumor
specimen was cut into small pieces, removing blood vessels, then resus-
pended in trypsin solution (Gibco, Invitrogen) and incubated at 37°C for
30minutes. During the incubation, the suspension was pipetted up and
down several times for total digestion of the tissues. The isolated cells
were grown in DMEM-10. The established cell lines were characterized
for the expression of glial fibrillary acidic protein (GFAP) and Nestin by
immunocytochemistry (Figure W1).
Authentication of cell lines was performed by IdentiCell Laboratories
[Department of Molecular Medicine (MOMA), Aarhus University
Hospital Skejby, Århus, Denmark] in August 2011. Genotyping con-
firmed the complete identity of all cell lines, with the exception of
U373, which was shown to be a subclone of the U251 cell line.
Drugs
Cediranib, sunitinib, and imatinib were obtained from Selleck
Chemicals (Houston, TX) and temozolomide was obtained from
Sigma-Aldrich (Sintra, Portugal). All the drugs were prepared as
stock solutions in DMSO and stored at −20°C. The drugs were sub-
sequently prepared as intermediate dilutions in DMSO to obtain an
equal quantity of DMSO (1% final concentration) in each of the
conditions studied. In all experimental conditions, the drugs were
diluted in 0.5% FBS culture medium (DMEM-0.5) to a final concen-
tration of 1% DMSO. Vehicle control (1% DMSO, final concentra-
tion) was also used in all experiments.
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Cell Viability Assay
To determine the concentration at which 50% of the cell growth
is inhibited by drug treatment (IC50 concentration), the cells were
plated into 96-well plates at a density of 2 × 103 cells per well and
allowed to adhere overnight in DMEM-10. Subsequently, the cells
were treated with increasing concentrations of the drugs diluted in
DMEM-0.5. After 72 hours, cell viability was quantified using
CellTiter 96 Aqueous Cell Proliferation Assay (MTS) (Promega,
Madison, WI). The results were expressed as mean viable cells rela-
tively to DMSO alone (considered as 100% viability) ± SD. The IC50
concentration was calculated by nonlinear regression analysis using
GraphPad Prism software. Combination studies with temozolomide
were done using the same protocol, and the results were expressed as
mean viable cells relatively to the condition of the fixed drug alone
(considered as 100% viability) ± SD. Drug interactions were analyzed
using CalcuSyn software. Determination of synergy was quantified by
the combination index (CI).
To assess the effect of a fixed concentration of the drug in cellular
viability over time, the cells were plated into 96-well plates at a density
of 1 × 103 cells per well and allowed to adhere overnight in DMEM-10.
Next, the viable cells were quantified using MTS assay and used as
time 0 of the experience. Then, the cells were incubated with fixed con-
centrations of the drugs diluted in DMEM-0.5 during 24, 48, and
72 hours. At the end of each time point, cell viability was again assessed
by MTS assay. The results were calibrated to the starting viability (time
0 hour, considered as 100% of viability) and expressed as the means ±
SD. Both assays were done in triplicate at least three times.
Cell Cycle Analysis
The cells were plated in a six-well plate at a density of 2 × 105 cells per
well and allowed to adhere overnight. After 6 hours of serum starvation,
the cells were incubated for 48 hours with fixed concentrations of the
drugs diluted in DMEM-0.5. Cells were trypsinized and fixed in 70%
ethanol for at least 30 minutes and then stained during 1 hour at 50°C
with propidium iodide (PI) solution [20 μg/ml PI and 250 μg/ml
RNAse in a solution of 0.1% Triton X-100 in phosphate-buffered
saline (PBS)]. Cell cycle analysis of the PI-stained cells was performed
by flow cytometry (LSRII; BD Biosciences, San Jose, CA). The per-
centage of cells in each phase of the cell cycle was determined using
FlowJo version 7.6.3, as described [39].
Wound Healing Migration Assay
The cells were seeded in six-well plates and cultured in DMEM-10
to at least 95% of confluence. Monolayer cells were washed with PBS,
scraped with a plastic 200-μl pipette tip, and incubated with fixed con-
centrations of the drugs diluted in DMEM-0.5. The “wounded” areas
were photographed by phase contrast microscopy after 0 and 48 hours.
The relative migration distance was calculated by the following for-
mula: percentage of wound closure (%) = 100(A − B)/A, where A is
the width of cell wounds before incubation, and B is the width of cell
wounds after incubation [39].
Matrigel Invasion Assay
Invasion of the cells was measured using BD BioCoat Matrigel inva-
sion chambers (BD Biosciences), as indicated by the manufacturer.
Briefly, 2.5 × 104 cells were plated in the matrigel-coated 24-well trans-
well inserts in DMEM-0.5 containing fixed concentration of the drugs.
DMEM-10 was used as chemoattractant. The cells were allowed to
invade for 48 hours. The invasive cells, attached to the insert membrane,
were fixed with methanol and stained with hematoxylin. The invasive
cells were photographed at ×40 magnification microscope and counted
in all the fields of the membrane. The results were expressed in relation
to the DMSO control (considered as 100% of invasion) as the mean
percentage of invasion ± SD.
Chick Chorioallantoic Membrane Assay
To assess in vivo tumor proliferation and angiogenesis, we used the
chorioallantoic membrane (CAM) assay, as previously described [39–
41]. Fertilized chicken eggs were incubated at 37°C and 70% humidity,
and on day 3 of development, a window was made into the shell and
the eggs were returned to the incubator. On day 9, small plastic rings
were placed on the CAM. For angiogenesis assessment, 20 μl of 0.5%
FBS culture medium containing fixed concentration of the drugs was
injected in the ring wall over the CAM on day 14. For tumor formation
evaluation, 3 × 106 cells were resuspended in 20 μl of DMEMmedium
and injected in the rings over the CAM on day 10. On day 14, the
tumors formed were photographed in ovo using a stereomicroscope
(Olympus S2x16). Next, 20 μl of 0.5% FBS culture medium contain-
ing 5 μM cediranib or vehicle control was injected under the tumors.
At day 17 (72 hours of incubation with the drug), the tumors were
again photographed in ovo. The chickens were sacrificed at −80°C for
10 minutes, and the tumors or CAM alone was fixed with paraformal-
dehyde at 4% and photographed ex ovo. The perimeter of the tumors
was measured using Cell B software (Olympus) in ovo at days 14 and
17. The results were expressed as mean percentage of tumor growth
for each group, from day 14 (considered as 0%) to day 17, ± SD.
For blood vessel counting, photographs were taken at day 17 ex ovo,
and the results were expressed as the mean of the vessels counted for
each group of treatments ± SD.
Western Blot and Human RTK Arrays
To assess the effect of the drugs on the inhibition of intracellular
signaling pathways and RTKs, the cells were cultured in DMEM-10
in T25 culture flasks, allowed to grow to 85% of confluence and then
serum starved for 2 hours and incubated with the drugs, diluted in
DMEM-0.5, by 2 hours. To assess apoptosis, cells were incubated
with only one concentration of each drug and incubated for 12, 24,
and 48 hours. At the indicated time points, the cells were washed
and scraped in cold PBS and lysed in buffer containing 50 mM Tris
(pH7.6–8), 150mMNaCl, 5mMEDTA, 1mMNa3VO4, 10mMNaF,
10 mM sodium pyrophosphate, 1% NP-40, and 1/7 of protease cock-
tail inhibitors (Roche, Amadora, Portugal). Western blot analysis was
done using standard 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, loading 20 μg of protein per lane. All the antibodies
were used as recommended by the manufacturer (see Supplementary
Materials and Methods for antibody information). Concerning the
assessment of RTK phosphorylation, a proteome Profiler human
phospho-RTK antibody array (ARY001; R&D Systems, Minneapolis,
MN) was used according to the manufacturer’s instructions. Briefly,
a total of 500 μg of fresh protein lysates was incubated overnight at
4°C with nitrocellulose membranes dotted with duplicated spots for
42 anti-RTK and control antibodies. Bound phospho-RTKs were incu-
bated with a pan anti–phosphotyrosine-HRP antibody for 2 hours at
room temperature.
Blot detection was done by chemiluminescence (ECL Western
Blotting Detection Reagents, RPN2109; GE Healthcare, Piscataway,
NJ) in ImageQuant LAS 4000 mini (GE Healthcare) or using X100
Hyperfilm ECL (Amersham, GE Healthcare).
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Statistical Analysis
Single comparisons between the different conditions studied were
done using Student’s t test, and differences between groups were tested
using two-way analysis of variance. Statistical analysis was done using
GraphPad Prism version 5. The level of significance in all the statistical
analyses was set at P < .05.
Results
Efficacy of Cediranib, Sunitinib, and Imatinib in
Glioblastoma Cells
To compare the in vitro efficacy of cediranib, sunitinib, and imatinib
treatment in glioblastomas, we determined the half-maximal inhibi-
tory concentrations (IC50) of each drug in a panel of eight glioblastoma
immortalized cell lines and in two primary glioblastoma cell cultures.
As shown in Table 1, cediranib was the most potent, displaying a mean
IC50 of 1.71 ± 0.97 μM (range, 0.47–4.17 μM), whereas the mean
IC50 for sunitinib was 2.92 ± 1.59 μM (range, 1.26–6.00 μM), and
the least efficient was imatinib (mean IC50 of 13.01 ± 6.09 μM; range,
6.28–23.20 μM). Notably, cediranib was clearly the most potent of
three RTKIs in the two primary culture glioblastoma cell lines analyzed
(HCB2 and HCB7).
To evaluate the potential combinatorial value of these drugs in the
context of standard glioblastoma therapy, we determined the IC50 of
temozolomide when administrated alone or in combination with fixed
doses of cediranib (1 μM to U251 and 2.5 μM to SNB-19), sunitinib
(2.5 μM to U251 and 5 μM to SNB-19), and imatinib (5 μM to
U251 and 15 μM to SNB-19). As exhibited in Table 2, we found that
both cediranib and sunitinib synergistically sensitize glioblastoma cells
to temozolomide treatment (CI < 1), whereas the effect of imatinib
seems to be merely additive (CI ∼ 1).
Biologic Effect of Cediranib, Sunitinib, and Imatinib
in Glioblastoma Cells
All drugs were able to reduce the viability of U251 cells over time,
as assessed by MTS assay, and this effect was dose dependent (Fig-
ure 1A). Consistently, the effects of cediranib and sunitinib over time
were the most pronounced, whereas imatinib displayed a somewhat
milder inhibitory potency. To determine whether decreased viability
was due to cytostatic or cytotoxic effects, we analyzed cell cycle distri-
bution (Figure 1B) and poly(ADP-ribose) polymerase (PARP) cleavage
(Figure 1C ). We observed that all drugs were cytostatic, with a signif-
icant reduction of cells in S phase of the cell cycle, mainly for higher
doses of treatment. Additionally, cell cycle arrest on the G2/M phase
was observed after cells were treated with 5 μM sunitinib, and a sig-
nificant reduction of cells in G0/G1 was observed after cediranib treat-
ment. A statistically significant higher percentage of apoptotic cells
(sub-G0) was detected only after treatment with 5 μM cediranib
(Figure 1B). In agreement, a striking effect on PARP cleavage was
detected only after high-dose cediranib treatment, whereas sunitinib
and imatinib promoted only minor PARP cleavage (Figure 1C ). Taken
together, these results suggest that the high sensitivity that glioblastoma
cells show to cediranib likely results from its concomitant cytostatic and
cytotoxic effects.
Next, we addressed whether cediranib, sunitinib, or imatinib could
impair cell migration and invasion in vitro (Figure 2). Using a wound
healing migration assay, we observed that all the drugs, at higher doses,
significantly inhibited cell migration and that, similar to the other
assays, cediranib was the most efficient drug at the concentrations
analyzed (Figure 2A). In contrast, only cediranib was able to impair cell
invasion in a matrigel invasion assay. Surprisingly, imatinib promoted
the invasion of the cells (Figure 2B).
The biologic effects of cediranib on viability, cell cycle, apoptosis,
migration, and invasion were confirmed in another cell line (SNB-19;
Figure W2). The effects of sunitinib and imatinib on viability, cell
cycle, and apoptosis were comparable in both cell lines analyzed,
whereas the effects on migration and invasion appeared to be cell type
specific, since, in contrast to the observations in U251 cells, imatinib
had no effect on cellular migration and invasion, and sunitinib effi-
ciently inhibited invasion of SNB-19 cells (Figure W2).
To evaluate whether the antineoplastic effect of cediranib also
happens in vivo, we induced the formation of tumors by injection of
U251 cells in the CAM (Figure 3). From day 14 to day 17 of embryo
development, we observed a mean growth of 69.1 ± 40.1% in the
tumors treated with DMSO. In contrast, tumors treated with 5 μM
cediranib showed a reduction of 59.8 ± 32.1% of the tumor growth
(Figure 3B). Additionally, the number of blood vessels recruited to
the tumors treated with cediranib was significantly reduced compared
to the tumors treated with DMSO alone (mean 33.3 ± 11.9 vs 48.3 ±
14.2 blood vessels, respectively; P < .05; Figure 3C ). Moreover, we
further confirmed that all the drugs are antiangiogenic, with a signifi-
cant reduction (P < .05) on the number of blood vessels formed after
CAM treatment with 5 μM cediranib, 5 μM sunitinib, and 15 μM
imatinib when compared to the drug vehicle (Figure W3).
Identification of Novel RTK Targets of Imatinib, Cediranib,
and Sunitinib in Glioblastoma Cells
To characterize the molecular basis for the differential sensitivity of
glioblastoma cells to the three drugs, we initially characterized the
Table 1. IC50 for Imatinib, Sunitinib, and Cediranib in Glioblastoma Cell Lines.
Cell Line Mean IC50 ± SD (μM)*
Imatinib Sunitinib Cediranib
U251 8.3 ± 1.65 1.26 ± 0.21 1.36 ± 0.41
SNB-19 16.93 ± 0.11 6.00 ± 0.35 2.05 ± 1.34
U373 20.50 ± 0.71 3.70 ± 0.53 4.17 ± 0.75
SW1783 8.94 ± 0.76 3.23 ± 0.32 1.55 ± 0.31
U-87 MG 23.20 ± 3.11 1.38 ± 0.45 1.96 ± 0.91
GAMG 6.28 ± 0.04 1.48 ± 0.49 0.47 ± 0.35
SW1088 7.53 ± 2.16 1.68 ± 0.77 1.56 ± 0.86
A172 8.94 ± 0.23 4.87 ± 1.18 1.40 ± 0.14
HCB2 11.43 ± 0.61 3.05 ± 0.45 1.27 ± 0.29
HCB7 18.04 ± 1.75 2.59 ± 1.44 1.27 ± 0.10
Mean† 13.01 ± 6.09 2.92 ± 1.59 1.71 ± 0.97
*Mean of at least three independent experiments done in triplicate.
†Mean of the IC50 concentration (μM) for all cell lines.
Table 2. IC50 of Temozolomide in Combination with Cediranib, Sunitinib, and Imatinib.
U251 SNB
TMZ IC50 (μM) CI TMZ IC50 (μM) CI
TMZ alone 557.8 – 955.1
TMZ + CD 164.0 0.838 448.7 0.985
TMZ + SU 309.4 0.837 485.0 0.866
TMZ + IM 406.2 1.176 515.4 1.033
CD, cediranib; SU, sunitinib; IM, imatinib.
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immortalized cell lines for the presence of genomic alterations of
PDGFRA amplicon (4q12), in particular the PDGFRA, KIT, and
VEGFR2 genes (see Supplementary Materials and Methods). No
activating mutations were found in the hotspot exons of PDGFRA
and KIT oncogenes. By quantitative polymerase chain reaction
(qPCR), we found co-amplification of the three genes in U251,
SNB-19, and U373 cell lines. SW1783 cell line has co-amplification
of PDGFRA and KIT, and GAMG cell line has amplification of
Figure 1. Effect of cediranib, sunitinib, and imatinib on U251 cellular survival, cell cycle, apoptosis, migration, and invasion. (A) Cellular
viability was measured at 24, 48, and 72 hours by MTS. (B) Cell cycle analysis was done at a 48-hour time point by flow cytometric
analysis of PI-stained cells. (C) Apoptosis we assessed by Western blot for PARP cleavage.
Figure 2. Effect of cediranib, sunitinib, and imatinib on U251 cellular migration and invasion. (A) Migration was measured at 48 hours by
wound healing migration assay. The relative migration distance was calculated as indicated in Materials and Methods section and the
results are expressed as the means ± SD. (B) Invasion was assessed by Matrigel invasion assay. The results were expressed in relation
to the DMSO control (considered as 100% of invasion) as the mean percentage of invasion ± SD. (C) Representative pictures of invasion
assay (×40 magnification).
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PDGFRA (Table W1). Subsequently, to identify the basal levels of
RTK activation in the glioblastoma cell lines (including HCB7 primary
cell line), we used a phospho-RTK array to assess the levels of 42 RTKs
and observed that all the cell lines presented different basal levels of RTK
phosphorylation (Table W1).
Next, to identify the RTKs that are targets of imatinib and mainly
cediranib and sunitinib treatment in glioblastomas, we extended the
RTK array analysis to some of the cell lines treated with each drug
(Figures 4 and W4). As expected, we confirmed KIT and PDGFRA
as common targets for both sunitinib and cediranib. Additionally,
cediranib inhibited EGFR, EphA7, and AXL in all the cell lines tested
that showed constitutive activation of these RTKs. MET was inhibited
in the only cell line that showed basal activation of this particular
RTK (GAMG cells), whereas EphB2 phosphorylation was downregu-
lated in two of three cell lines (GAMG and HCB7). Sunitinib inhib-
ited EphB2 in two of two cell lines (U251 and GAMG) and ROR1 in
one of one (U251), whereas AXL was inhibited in SNB-19 cells but
not in U251 or GAMG (Figure 4B). Furthermore, we observed that
PDGFRA was the only target to imatinib in U251 cells (Figure 4).
In addition to RTK inhibition, we also observed activation of some
RTKs after sunitinib and imatinib treatment. In U251 cells, EphB6
and Tie-1 were activated upon imatinib treatment. After sunitinib
treatment, we found phosphorylation of EphA2 in U251 and GAMG
cell line and also of RET in U251 cell line. We did not detect any
significant increase in RTK phosphorylation after treatment with
cediranib (Figures 4A and W4A).
To validate the arrays, we performed Western blot analysis for
U251 cells with a specific antibody for EGFR phosphorylation
(Figure W4B).
Effect of Cediranib, Sunitinib, and Imatinib in Intracellular
Signaling Pathway Activation in Glioblastoma Cells
To further characterize the RTK inhibitors and assess whether their
effects could correlate with differential activation of intracellular signal-
ing pathways, we exposed U251 cells to increasing concentrations of
the three drugs. By Western blot, we assessed the activation levels of
some intermediates of the mitogen-activated protein kinase (MAPK),
AKT, JAK/STAT, and SRC pathways (Figure 5). Cediranib reduced
Figure 3. In vivo effect of cediranib on glioblastoma growth and angiogenesis. (A) Representative pictures (×16 magnification) of CAM
assay in ovo and ex ovo at days 14 and 17. (B) Tumor growth was measured as described in Materials and Methods section. The results
were expressed as mean percentage of tumor growth from day 14 (considered as 0%) to day 17 of development ± SD. (C) Counting of the
blood vessels ex ovo at day 17. The results were expressed as the mean number of vessels for each group of treatments ± SD. Differences
with P < .05 on the Student’s t test were considered statistically significant (*). A total of 12 eggs were used for tumor formation (six were
treated with cediranib and six with DMSO alone).
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the activation levels of extracellular signal-regulated kinase 1/2 (ERK1/2)
at low doses (0.5 and 1 μM) and completely inhibited the pathway
starting from 5 μM. A dose-dependent reduction of AKT activation
levels was also found in cells treated with cediranib. Moreover, the
activation levels of STAT3 seem to be inhibited after sunitinib and
imatinib treatment.
Discussion
Molecular therapies that targeted RTKs are promising therapeutic strat-
egies for glioblastoma tumors. However, the majority of preliminary
results of clinical trials are unsatisfactory and failed to show outcome
improvements, mainly because the predictive targets for therapy response
in glioblastomas remain to be identified; hence, it is believed that those
Figure 4. Cediranib, sunitinib, and imatinib targets on glioblastoma cells. (A) Representative pictures of phospho-RTK arrays for U251 cell
line. Each RTK is represented in duplicate in the arrays (two spots side by side), and four pairs of phosphotyrosine positive controls are
located in the corners of each array. (B) Other cell lines were treated with cediranib, sunitinib, and imatinib at the indicated concentrations,
and the RTKs that were targeted after drug treatment are shown in the table.
Figure 5. Effect of cediranib, sunitinib, and imatinib on intracellular signaling pathway activation in U251 cells. The cells were incubated
with increasing concentrations of the three drugs by 2 hours. By Western blot, we assess the activation levels of several intermediates
of the MAPK (p-ERK1/2 and p-p38), AKT (p-AKT), JAK/STAT (p-STAT3), and SRC (non-p-SRC Tyr527 and p-SRC Tyr416) pathways. The
levels of phosphorylation were compared with the corresponding total proteins.
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patients are not being properly selected for the therapy [24]. In the
present study, we intended to identify the specific RTK targets of two
RTKis (sunitinib and cediranib). Further, we aimed to determine, in vitro
and in vivo, the efficacy of these drugs in comparison to imatinib.
Hitherto, the antiproliferative effect of these drugs in glioblastomas
was unclear. The reports of the effect of imatinib on glioblastoma cell
proliferation impairment and cell cycle arrest are contradictory [42–
45], as well as its apoptosis or autophagy consequence effect [43,44].
Concerning sunitinib, only two studies addressed its in vitro effects
in glioblastomas, using a single cell line (U-87 MG), and found that
sunitinib impairs cell survival by apoptosis induction [28,46,47] and
induces cell cycle arrest in G2/M [28]. Regarding cediranib, there are
no studies reporting the effect of this drug in tumor cells in vitro. Two
preclinical in vivomodels showed an effect of cediranib in the reduction
of xenografted tumors [48,49]. The clinical studies on glioblastoma
patients showed that cediranib decreases the cell density in the central
area of the tumor [50] and controls tumor growth by normalizing
tumor vasculature in addition to alleviating edema [36,37]. Yet, one
preclinical study with xenografted models showed that cediranib con-
trols edema and prolongs survival but did not affect tumor growth [38].
In the present work, we found that all the drugs were effective against
a panel of 10 glioblastoma cell lines (two of them being primary cul-
tures), with cediranib being the most potent. Furthermore, we observed
in U251 cells that all the drugs impair cellular survival over time and in
a dose-dependent manner, and again, cediranib was the most effective,
even in the less sensitive cell line (SNB-19). By cell cycle analysis, we
observed that all the drugs are cytostatic and reduce the number of cells
in S phase. In the cells treated with sunitinib, cell cycle arrest in G2/M
phase was also found, as described before [28]. In contrast to the other
two drugs, cediranib showed to be also cytotoxic—inducing cell death
by apoptosis, as assessed by PARP cleavage. We further confirmed by
in vivo assays that cediranib displays simultaneously antiangiogenic and
antitumoral activity in glioblastomas.
Glioblastomas are highly invasive tumors and this feature influences
glioma survival and response to therapy [51]. Overall, we observed
in vitro that both sunitinib and cediranib inhibited cellular migration
and invasion. At variance, imatinib leads to a slight increase of both
migration and invasion in some cells. There are no in vitro studies in
the literature using cediranib in glioblastoma cells, precluding any
comparisons. Concerning sunitinib, previous works on U-87 MG cells
showed that sunitinib treatment was also associated with migration and
invasion reduction [28,46,47]. However, invasion inhibition was not
proved in vivo [28]. In respect to imatinib, there are only migration
studies, which also reported the antimigratory capabilities of the drug
in some cell lines and the absence of effect in others [52]. The effect of
imatinib in glioblastoma cell invasion, as far as we know, was never
reported before. Here, we observed that at least for U251 cells, imatinib
can actually promote invasion. This effect was described before for
other antiangiogenic drugs, such as bevacizumab [23].
The aforementioned effects are regulated by the intracellular sig-
naling cascades. In agreement with the higher and broader activity that
cediranib exhibited against glioblastoma cells, we found that cediranib
inhibited both MAPK and AKT pathways, as previously described [33].
Importantly, and in agreement with other studies [48,52], we
found that cediranib, as well as sunitinib, synergistically sensitizes
glioma cells to temozolomide. These findings suggest that combining
temozolomide with RTK inhibitor drugs may improve tumor control.
Besides the discrepant results in the preclinical models using the
three drugs we tested, it has been postulated by clinical trial results that
cediranib is the most promising to prolong patients’ survival [32,35].
Our study, comparing the three drugs for the first time, confirmed
in vitro the results achieved in the clinical trials, showing cediranib
as the most potent antiproliferative inhibitor. However, similar to
the clinical trials, we observed heterogeneous responses of the cells
to the same drugs, mainly in migration and invasion assays, suggesting
that each drug may have specific targets in glioblastoma cells that have
yet to be identified.
The main RTK targets for the pharmacological inhibition in glio-
blastomas have been EGFR, PDGFRA, KIT, and VEGFR2 [6].
PDGFRA, KIT, and VEGFR2 are reported to be overexpressed, re-
sulting from gene amplification without activating mutations [7–9].
VEGFR2, PDGFRA, and KIT are located side by side in the same
chromosomal region 4q12, and co-amplification of these three onco-
genes has been observed in glioblastoma patients [8,9]. Thus, to
identify the potential targets for imatinib, sunitinib, and cediranib in
glioblastomas, we first characterized the cell lines for the molecular
status (mutations and amplification) of KIT, PDGFRA, and VEGFR2.
No associations were found between the presence of those alterations
and the response of the cells to the drugs. Our results are in agreement
with clinical studies that failed to find associations between the pres-
ence of genomic alterations in these loci and response to sunitinib
and imatinib therapy [19,32]. Next, we assessed the phosphorylation
levels of 42 different RTKs, before and after treatment, using a human
phospho-RTK array. We found that glioblastoma cells have co-
activation of several RTKs simultaneously, as previously suggested by
others [53]. Recent studies suggested that RTK amplifications (mainly
EGFR and PDGFRA) in gliomas can occur in mosaic being hetero-
geneously distributed within single tumors [10–12]. Overall, those
findings reinforce the usage of RTK multitargeted therapies, such as
cediranib, for glioblastoma treatment. In the present work, we found
PDGFRA as the only target of imatinib in U251 cells, and both
PDGFRA and KIT were targets for cediranib and sunitinib as expected.
Importantly, additional and novel targets were identified in these cells,
such as EGFR, EphA7, AXL, MET, and EphB2 for cediranib and
EphB2, ROR1, and AXL for sunitinib. Phyllis and colleagues showed
that tumors expressing high levels of EGFR exhibited greater sensitiv-
ity to cediranib [49]. Here, we found that EGFR is one of the targets of
cediranib. Overall, those findings can suggest that EGFR expression/
activation can potentially be used to predict response to cediranib ther-
apy. The role of the remaining RTK targets that we identified in glio-
blastoma is unclear, and their predictive value for therapy response has
to be further explored.
In addition to RTK inhibition, we also observed activation of
EphB6 and Tie-1 after imatinib treatment and of EphA2 and RET after
sunitinib treatment. These observations, including the identification of
novel targets of cediranib and sunitinib in glioblastoma and the activa-
tion of particular RTKs in some cell lines upon sunitinib and imatinib,
but not cediranib, treatment, might be clinically relevant. The role of
these alterations in the modulation of therapy response has yet to be
determined for glioblastomas. Usually, this is a phenomenon associated
with resistance of other cancers to therapy [54,55].
In conclusion, our study constitute the first comparative study
of the efficacy of imatinib, sunitinib, and cediranib in glioblastoma
cells and found that cediranib, either alone or in combination with
temozolomide, is the most effective drug not only through its anti-
angiogenic activity but also as a consequence of its greater antitumoral
activity. Importantly, we identified the RTK targets of cediranib and
sunitinib in glioblastomas, some of which are reported for the first time.
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This study constitutes a step forward in the identification of potential
predictive biomarkers to anti-RTK therapies in glioblastomas that
may allow, in the future, the rational selection of patients for specific
targeted therapies.
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Supplementary Materials and Methods
Molecular Characterization of PDGFRA, KIT, and VEGFR2
DNA isolation was performed using TRIzol reagent (Invitrogen)
as indicated by the manufacturer. The screening of mutations in the
hotspot exons of KIT (exons 9, 11, 13, and 17) and PDFGFRA
(exons 12, 14 and 18) was done by PCR–single-strand conformation
polymorphism (SSCP), as previously described [1,2]. Assessment of
PDGFRA, KIT, and VEGFR2 gene amplification was performed by
quantitative PCR, as previously described [1–3]. Primers and probes
for PDGFRA and KIT amplification were previously described [1–3].
For VEGFR2, the primers and probes were the following: 5′-TGAAA-
GAGACACAGGAAATTACACTG-3′ (forward primer), 5′-CATAA-
TAAATCTTGGGCAGAGAGG-3′ (reverse primer), 5′-CACAAC-
CAGAGAGACCACATGGCTC-FL (donator probe), LC640-GCT-
TCTCCTTTGAAATGGGATTGGTAAGGA-3′ (acceptor probe).
Antibodies Used in the Western Blot and Array Validation
To assess the activation of intracellular signaling pathways, the anti-
bodies used were the following: phospho-p44/42 MAPK (Thr202/
Tyr204) (D13.14.4E); phospho-p38 MAPK (Thr180/Tyr182) (D3F9);
phospho-Akt (Ser473) (D9E); phospho-Stat3 (Tyr705) (D3A7); non–
phospho-Src (Tyr527); phospho-Src Family (Tyr416). The membranes
were stripped and incubated with antibodies to detect the total protein
levels as follows: p44/42 MAP kinase (137F5); p38 MAP kinase; Akt
(pan) (C67E7); Stat3; Src (36D10). An antibody against PARP expres-
sion was used for apoptosis detection. When necessary, β-actin (dilu-
tion 1:300; Santa Cruz Biotechnology, Dallas, TX) was used as a
loading control.
For array validation, Western blot was performed with the same
lysates used for the arrays to detect EGFR phosphorylation with the
specific antibody phospho-EGFR (Y1068) (D7A5) from Cell Signal-
ing Technology (Danvers, MA). The antibody to detect total EGFR
(31G7; Zymed Laboratories, San Francisco, CA) was used as controls.
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Figure W1. Immunocytochemistry analysis for Nestin and GFAP in primary cell lines (HCB2 and HCB7). U251 cell line was used as positive
control. Immunocytochemistry was done with standard protocols, using specific primary antibodies for Nestin (1:200; Novus Biological,
Cambridge, United Kingdom) and GFAP (1:1000; DakoCytomation, Glostrup, Denmark), followed by incubation with a biotinylated sec-
ondary antibody and revealed according to the streptavidin-biotin peroxidase complex system with visualization by 3,3′-diamonobenzidine
chromogen. The pictures were taken at ×200 magnification.
Figure W2. Effect of cediranib, sunitinib, and imatinib on SNB-19 cellular survival, cell cycle, migration, invasion, and apoptosis. (A) Cellular
viability was measured at 24, 48, and 72 hours by MTS. (B) Cell cycle analysis was done at a 48-hour time point by flow cytometric analysis
of PI-stained cells. (C) Migration was measured at 48 hours by wound healing migration assay. The relative migration distance was cal-
culated as indicated in Materials and Methods section. (D) Invasion was assessed by matrigel invasion assay. (E) Apoptosis we assessed
byWestern blot for PARP cleavage. In all the experiments, the cells were incubated with one/two concentrations of each drug and also with
the vehicle alone (DMSO) at the time points indicated. Data on A, B, C, and D are represented as the means ± SD, and differences with
P < .05 on Student’s t test were considered statistically significant (*).
Figure W3. Effect of cediranib, sunitinib, and imatinib on angio-
genesis. To assess angiogenesis, we performed CAM assay as
described in Materials and Methods section. On day 14 of develop-
ment, 20 μl of 0.5% FBS culture medium containing fixed concen-
tration of the drugs (indicated in the graph) or DMSO alone was
injected over the CAM. At day 17, the blood vessels were counted
ex ovo. The results were expressed as the mean of the vessels
counted for each group of treatments ± SD. Differences with P <
.05 on the Student’s t test were considered statistically significant
(*). A total of 20 eggs were used for angiogenesis assessment (five
were treated with cediranib, five with sunitinib, five with imatinib,
and five with DMSO alone).
Table W1. Molecular Alterations of RTKs in Glioblastoma Cell Lines.
Cell Line Gene Amplification Gene Mutations RTK Phosphorylation*
PDGFRA KIT VEGFR2 PDGFRA KIT
U251 Amp Amp Amp wt wt EGFR; EphB2; PDGFRA; ROR1; EphA7; AXL
SNB-19 Amp Amp Amp wt wt EGFR; PDGFRA; EphA7; AXL
U373 Amp Amp Amp wt wt EGFR
SW1783 Amp Amp NA wt wt EGFR; MSP; HER4; EphB2; PDGFRB; FGFR3; M-CSFR; ROR1
U-87 MG NA NA NA wt wt EGFR; MET; EphA7; MSP; HER4; EphB2; VEGFR2; FGFR3; M-CSFR; RET; ROR1
GAMG Amp NA NA wt wt EGFR; EphA7; FGFR3; AXL; KIT; MET; EphB2
SW1088 NA NA NA wt wt EGFR; EphB2; PDGFRB; ROR1
A172 NA NA NA wt wt EGFR; EphB2; PDGFRB; ROR1; AXL
Amp, amplified; NA, not amplified; wt, wild type.
*Assessed using a phospho_RTK array.
Figure W4. Cediranib and sunitinib targets in glioblastoma cells. (A) To identify the RTKs that are activated in the glioblastoma cell lines
before and after cediranib and sunitinib treatment (5 μM by 2 hours), we used a phospho-RTK array (GAMG, SNB-19, U373, and HCB7
cell lines). Each RTK is represented in duplicate in the arrays (two spots side by side), and in addition, four pairs of phosphotyrosine
positive controls are in the corners of each array. (B) To validate the arrays, we performed Western blot analysis with specific antibodies
for EGFR phosphorylated proteins in U251 cell line treated with the three drugs.
